Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,605
Roche Holding AG News & Analysis
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
stocks
10 global stocks for a recession
These undervalued stocks come from high-quality companies in defensive sectors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,420.50 | 75.50 | -0.89% |
| CAC 40 | 7,380.74 | 67.18 | 0.92% |
| DAX 40 | 19,909.14 | 75.18 | -0.38% |
| Dow JONES (US) | 42,544.22 | 29.51 | -0.07% |
| FTSE 100 | 8,173.02 | 52.01 | 0.64% |
| HKSE | 20,059.95 | 18.53 | 0.09% |
| NASDAQ | 19,310.79 | 175.99 | -0.90% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,881.63 | 25.31 | -0.43% |
| S&P/ASX 200 | 8,159.10 | 75.90 | -0.92% |
| SSE Composite Index | 3,351.76 | 55.56 | -1.63% |